NASDAQ
The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, effective December 22, 2025....
Balyasny Asset Management L.P. raised its holdings in shares of Biogen Inc. (NASDAQ: BIIB) by 5.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities ...
Daiwa Securities Group Inc. lessened its holdings in Biogen Inc. (NASDAQ: BIIB) by 9.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The ...
Federated Hermes Inc. raised its holdings in shares of Biogen Inc. (NASDAQ: BIIB) by 16.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission...
Pre-Market Stock Futures: Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of 2025, and the odds still heavily favor a 25-basis-...
TORONTO--(BUSINESS WIRE)--Biogen Canada Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) for ZURZUVAE™ (zuranolone) for the treatment of moderate or severe postpartum de...
TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizu...
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to 8.3 years in low-amyloid group who started tre...
No price data available for this timeframe.